Adolescent Depression Screening, Risk Assessment, and Treatment
Clinical Practice Update — Screening and Initial Management in the Primary Care Setting
This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.
- Clinical Focus
- Universal screening, suicide risk assessment, and initial management of depression in adolescents
- Target Audience
- Pediatricians, family physicians, nurse practitioners, residents, school health clinicians
- Setting
- Primary care, adolescent medicine, school-based health, integrated behavioral health
- Source Evidence
- •USPSTF Recommendation: Depression and Suicide Risk Screening in Children and Adolescents (2022)
- •GLAD-PC Part I — Identification, Assessment, and Initial Management (Pediatrics, 2018; reaffirmed 2025)
- •GLAD-PC Part II — Treatment and Ongoing Management (Pediatrics, 2018)
- •FDA Boxed Warning on Antidepressants and Pediatric Suicidality (2017 labeling)
Key Clinical Takeaways
Effective adolescent depression screening turns a brief office visit into a chance to catch a common, treatable, and sometimes dangerous condition early. The points below distill current evidence into actionable rules for identifying depression, gauging suicide risk, and starting initial management before a single prescription is written.
- 1Screen every adolescent aged 12 and older at least once a year, even when they look well and raise no concerns themselves.
- 2Use a validated self-report tool such as the PHQ-A to make adolescent depression screening systematic rather than dependent on a clinician’s impression.
- 3Interview the teen alone for part of every visit — disclosure of mood symptoms, self-harm, and substance use rises sharply without a parent in the room.
- 4Treat every positive screen as a prompt for a direct, calm question about suicidal thoughts; asking does not plant the idea.
- 5Confirm the diagnosis against DSM-5 criteria and grade severity as mild, moderate, or severe — severity drives the first treatment decision.
- 6For mild depression, begin with active monitoring and support over roughly six weeks before reaching for medication or formal therapy.
- 7When medication is indicated, fluoxetine and escitalopram are the only SSRIs with pediatric depression approval and the most reasonable first choices.
- 8Counsel families about the boxed warning and monitor closely in the first weeks, when treatment-emergent suicidal thoughts are most likely to surface.
Who Should Receive Adolescent Depression Screening
Two evidence frameworks converge on the same starting point. Independent expert panels recommend routine adolescent depression screening for everyone aged 12 to 18, and primary-care-specific guidance extends annual screening through the late teens at health maintenance visits. The decision to screen is therefore not a judgment call made case by case — it applies to the whole adolescent panel.
Perform universal screening for major depression at least annually in every adolescent aged 12 and older, regardless of presenting complaint or apparent risk.
Strong Rec Moderate Evidence USPSTF 2022 GLAD-PC 2018Evaluate for depression at any visit when a high-risk adolescent presents, even if a routine annual screen was recently negative. Risk factors include a prior episode, a family history of mood disorder, chronic illness, trauma or loss, substance use, and emerging gender or sexuality concerns without support.
Strong Rec Moderate Evidence GLAD-PC 2018Avoid relying on routine screening alone in children 11 and younger, where the evidence supporting a standardized tool in primary care is insufficient; assess these younger children clinically when symptoms or risk factors are present.
Conditional Rec Low Evidence USPSTF 2022How to Perform Adolescent Depression Screening
A screen is only as good as the conditions around it. The instrument matters, but so does confidentiality, the chance to speak with the teen alone, and a clear plan for what a positive result triggers. Validated self-report tools accurately identify depression in adolescents in primary care, which is why a structured questionnaire outperforms unstructured impression.
Administer a validated adolescent self-report instrument — the PHQ-A, the full PHQ-9 adapted for teens, or a comparable tool — rather than relying on open-ended conversation alone to detect depression.
Strong Rec High Evidence USPSTF 2022 GLAD-PC 2018Interview the adolescent confidentially for at least part of the visit. Explain the limits of confidentiality up front, including that imminent safety concerns must be shared, so trust is set before sensitive questions begin.
Strong Rec Moderate Evidence GLAD-PC 2018Corroborate the self-report with collateral history from a parent or caregiver where possible, recognizing that teens and adults often report different symptoms and that agreement between them is frequently modest.
Moderate Rec Low Evidence GLAD-PC 2018Prepare the practice before screening begins. Establish a workflow for positive results, identify referral partners, and agree on who follows up — screening without a response plan creates risk rather than reducing it.
Strong Rec Low Evidence GLAD-PC 2018Common Screening Tools at a Glance
| Tool | Items & Format | Best Use in Practice | Practical Tips |
|---|---|---|---|
| PHQ-A | Self-report, adolescent-adapted depression items | Annual universal screening and severity tracking | Includes a self-harm item — never skip reviewing it in person |
| PHQ-9 (modified for teens) | 9-item self-report, scored 0–27 | Quantifying severity and monitoring response over time | Higher totals broadly track with greater severity; use trend, not a single number |
| Brief self-harm/suicide query | Short structured questions on ideation | Layered onto any positive depression screen | A focused query is a prompt for conversation, not a substitute for clinical judgment |
Assessing Suicide Risk After a Positive Screen
A positive depression screen and a suicide risk question belong in the same encounter. Expert panels concluded that the evidence is not yet sufficient to recommend universal standalone suicide-risk screening of all youth, but that is a statement about population screening — not a reason to skip risk assessment in an adolescent who has already screened positive for depression.
Perform a focused suicide risk assessment in every adolescent who screens positive for depression or who endorses self-harm on a questionnaire item. Ask directly about thoughts of death, intent, and any plan.
Strong Rec Moderate Evidence GLAD-PC 2018Explore access to lethal means with the family, and counsel on reducing that access at home. Frame it as a routine safety step that applies to every household, not an accusation.
Strong Rec Moderate Evidence GLAD-PC 2018Refer urgently for emergency evaluation when an adolescent reports active suicidal intent, a plan, a recent attempt, or cannot engage in a safety plan. Do not leave a high-risk teen unattended.
Strong Rec Low Evidence GLAD-PC 2018Clinical Decision Pathway
A practical, question-based route from a positive screen to an initial plan. Work through the questions in order at the first visit.
Initial Management Before Medication
Much of the work after a positive screen happens before any prescription. Psychoeducation, family engagement, a safety plan, and a defined follow-up interval form the foundation that every later decision builds on. For mild presentations, this foundation may be the whole of the initial treatment.
Establish a safety plan with the adolescent and a caregiver that names personal warning signs, coping steps, supportive people to contact, and how to reach urgent help. Revisit it at follow-up.
Strong Rec Low Evidence GLAD-PC 2018Provide psychoeducation to the teen and family that frames depression as a real, common, and treatable medical condition, and explains what active monitoring and treatment will involve.
Strong Rec Low Evidence GLAD-PC 2018For mild depression, begin with active monitoring — supportive contact, self-management guidance, and regular reassessment over roughly six weeks — before initiating medication or formal psychotherapy.
Moderate Rec Moderate Evidence GLAD-PC 2018Offer an evidence-based psychotherapy such as cognitive behavioural therapy or interpersonal therapy for adolescents as a first-line option in moderate to severe depression, alone or alongside medication.
Strong Rec High Evidence GLAD-PC 2018When to Start Medication
Medication enters the picture for moderate to severe depression, or for milder depression that has not responded to active monitoring and support. Two SSRIs carry pediatric depression approval, and effective doses in adolescents generally start lower than adult regimens. The table below is organized by clinical scenario rather than by drug class, with practical prescribing notes attached.
Prescribe an SSRI with pediatric depression evidence — fluoxetine or escitalopram — as the preferred first-line agent when medication is indicated for moderate to severe depression.
Strong Rec High Evidence GLAD-PC 2018 FDA LabelingStart low and titrate gradually, allowing several weeks at an adequate dose before judging response. Premature dose escalation and early discontinuation are both common avoidable errors.
Moderate Rec Moderate Evidence GLAD-PC 2018Do not use paroxetine as a first-line antidepressant in adolescents, given an unfavourable balance of efficacy and safety signals in this age group compared with alternatives.
Against Moderate Evidence FDA Safety AdvisoryFirst-Line Medication by Clinical Scenario
| Clinical Scenario | Reasonable First Agent | Pediatric Approval | Prescribing Notes |
|---|---|---|---|
| Moderate to severe MDD, age 8–17, no contraindication | Fluoxetine | FDA-approved for pediatric depression | Long half-life forgives missed doses; the most studied SSRI in this age group |
| Moderate to severe MDD, age 12–17 | Escitalopram | FDA-approved for adolescent depression | Reasonable alternative if fluoxetine is unsuitable; review QT-prolonging co-medications |
| Inadequate response to a first adequate SSRI trial | Switch SSRI or add therapy | Varies by agent | Confirm adherence and adequate duration first; involve or refer to specialty care |
| Any adolescent starting an antidepressant | Structured monitoring | — | Boxed warning applies to all antidepressants under age 25; schedule early review |
Monitoring and Follow-Up
The first weeks after starting treatment are when both improvement and adverse effects declare themselves. A repeatable monitoring routine — symptom rating, safety check, and side-effect review — keeps follow-up structured rather than ad hoc.
| What to Track | When to Check | What to Look For | Common Pitfalls |
|---|---|---|---|
| Symptom severity (repeat self-report) | Early after starting treatment, then at regular intervals | Falling scores and improving function over time | Judging a single score instead of the trend across visits |
| Suicidal thoughts and safety | Every contact, especially the first weeks on medication | New or worsening ideation, agitation, or sleep disruption | Assuming the safety conversation only needs to happen once |
| SSRI adverse effects | At each early follow-up after initiation or dose change | Activation, GI upset, sleep change; rarely, a manic switch | Mistaking early activation for worsening depression and stopping abruptly |
| Treatment engagement | Ongoing | Attendance at therapy, adherence, family support | Recording a referral as done without confirming the teen actually connected |
Monitor actively for the emergence of adverse events, including treatment-emergent suicidal thoughts, during the early phase of antidepressant treatment, with contact arranged soon after starting or changing a dose.
Strong Rec Moderate Evidence GLAD-PC 2018 FDA LabelingReassess the diagnosis and the plan if an adolescent does not improve after an adequate trial, and involve or refer to mental health specialty care for partial or absent response.
Moderate Rec Low Evidence GLAD-PC 2018Evidence in Context
What the evidence supports, where the major frameworks line up, and where genuine uncertainty remains.
Where the screening frameworks agree
Independent prevention panels and primary-care guidance agree that adolescents aged 12 and older should be screened for depression with validated tools, that a positive screen requires diagnostic confirmation rather than automatic treatment, and that any screening program must be backed by a plan for diagnosis, treatment, and follow-up.
Where uncertainty remains
The evidence is judged insufficient to recommend routine depression screening in children 11 and younger using a standardized primary-care tool, and insufficient to recommend universal standalone suicide-risk screening across all youth. These are gaps in the evidence base, not findings that screening causes harm.
What the treatment trials show
Randomized evidence supports both SSRIs and structured psychotherapies for adolescent depression, with combination therapy often performing well. Across studies, combining medication with cognitive behavioural therapy has tended to produce strong outcomes, and pairing an SSRI with therapy has been associated with lower rates of treatment-emergent suicidality than SSRI monotherapy in some trials.
Reading the boxed warning in context
The antidepressant boxed warning reflects a small but measurable increase in suicidal thoughts and behaviour, concentrated in the early treatment phase, observed when these agents were studied in those under 25. The clinical response is intensified monitoring rather than avoidance, because the suicide risk of untreated moderate to severe depression is itself substantial.
References
- 1.US Preventive Services Task Force. Screening for Depression and Suicide Risk in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(15):1534–1542. doi:10.1001/jama.2022.16946
- 2.Zuckerbrot RA, Cheung A, Jensen PS, et al; GLAD-PC Steering Group. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part I. Practice Preparation, Identification, Assessment, and Initial Management. Pediatrics. 2018;141(3):e20174081. doi:10.1542/peds.2017-4081
- 3.Cheung AH, Zuckerbrot RA, Jensen PS, et al; GLAD-PC Steering Group. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part II. Treatment and Ongoing Management. Pediatrics. 2018;141(3):e20174082. doi:10.1542/peds.2017-4082
- 4.US Food and Drug Administration. Fluoxetine: Full Prescribing Information, Boxed Warning. accessdata.fda.gov
How to Read the Evidence Tags
Every recommendation carries two tags — one for recommendation strength and one for evidence quality — using Medaptly’s own simplified interpretation of the underlying source grading.
Recommendation Strength
| Tag | What It Means |
|---|---|
| Strong Rec | High-quality evidence broadly supports this action. |
| Moderate Rec | The weight of evidence favours this action. |
| Conditional Rec | The benefit is less certain — individualise. |
| Against | Evidence shows no benefit or potential harm. |
Evidence Quality
| Tag | What It Means |
|---|---|
| High Evidence | Multiple well-designed RCTs or high-quality meta-analyses. |
| Moderate Evidence | Single RCT or large observational studies. |
| Low Evidence | Expert consensus or small studies. |